Related Experiment Video
Updated: Jul 4, 2025
08:11
Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
2.8K
Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem
Maurizio Giuseppe Abrignani1, Edoardo Gronda2, Marco Marini3
1Chairperson Working Group On Cardiological Chronicity ANMCO, Cardiology Unit, P. Borsellino Hospital, ASP Trapani, M.D., Via F. Crispi 6, 91025, Marsala, Italy. maur.abri60@gmail.com.
Cardiovascular Drugs and Therapy
|January 30, 2024
Summary
Hyperkalaemia is common in cardiovascular patients, increasing mortality and hindering essential treatments. New potassium binders offer improved management options for both acute and chronic conditions.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Hyperkalaemia is a frequent electrolyte disorder in cardiovascular disease (CVD) patients.
- It is associated with increased mortality, cardiovascular morbidity, and hospitalizations.
- Conditions like advanced age, diabetes, and chronic kidney disease contribute to hyperkalaemia.
Purpose of the Study:
- To review the burden of hyperkalaemia in cardiovascular patients.
- To discuss its direct and indirect effects.
- To outline current and emerging therapeutic options for acute and chronic hyperkalaemia.
Main Methods:
- Literature review of population-based cohort studies and clinical trials.
- Analysis of the impact of hyperkalaemia on CVD management.
- Evaluation of existing and novel therapeutic agents for hyperkalaemia.
Main Results:
- Up to 40% of patients in cohort studies develop hyperkalaemia.
- Hyperkalaemia often necessitates withholding or contraindicating renin-angiotensin-aldosterone inhibitors (RAASi).
- New potassium binders, patiromer and sodium zirconium cyclosilicate, demonstrate safety and efficacy.
Conclusions:
- Hyperkalaemia poses a significant challenge in cardiovascular patient care.
- Effective management is crucial to avoid treatment limitations and improve outcomes.
- Novel potassium binders represent a significant advancement in managing hyperkalaemia.
Keywords:
Chronic kidney diseaseEpidemiologyHeart failureHyperkalaemiaPatiromer sorbitex calciumPotassium bindersSodium zirconium cyclosilicateMore Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
588
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
746
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
746
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
560
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
560
01:22Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
999
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
999